Cargando…

Antibody-drug conjugates in HER2-positive breast cancer

Antibody-drug conjugates (ADCs) combine the high specificity of monoclonal antibodies with the high anti-tumor activity of small molecular cytotoxic payloads. The anti-tumor activity of ADCs is mainly achieved by the direct blocking of the receptor by monoclonal antibodies, direct action and bystand...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Lixi, Zhang, Di, Liu, Binliang, Lv, Dan, Zhai, Jingtong, Guan, Xiuwen, Yi, Zongbi, Ma, Fei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Review Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8812658/ https://www.ncbi.nlm.nih.gov/pubmed/34935688 http://dx.doi.org/10.1097/CM9.0000000000001932

Ejemplares similares

Molecular landscape of TP53 mutations in breast cancer and their utility for predicting the response to HER‐targeted therapy in HER2 amplification‐positive and HER2 mutation‐positive amplification‐negative patients
por: Liu, Binliang, et al.
Publicado: (2022)

Safety and efficacy of sirolimus combined with endocrine therapy in patients with advanced hormone receptor-positive breast cancer and the exploration of biomarkers
por: Yi, Zongbi, et al.
Publicado: (2020)

Molecular landscape and efficacy of HER2-targeted therapy in patients with HER2-mutated metastatic breast cancer
por: Yi, Zongbi, et al.
Publicado: (2020)

Everolimus in hormone receptor-positive metastatic breast cancer: PIK3CA mutation H1047R was a potential efficacy biomarker in a retrospective study
por: Yi, Zongbi, et al.
Publicado: (2019)

Gut Microbiota Profiling in Patients With HER2-Negative Metastatic Breast Cancer Receiving Metronomic Chemotherapy of Capecitabine Compared to Those Under Conventional Dosage
por: Guan, Xiuwen, et al.
Publicado: (2020)

Breast Cancer in Chinese Females Aged 25 Years and Younger
por: Li, Lixi, et al.
Publicado: (2021)

Longitudinal HER2 amplification tracked in circulating tumor DNA for therapeutic effect monitoring and prognostic evaluation in patients with breast cancer
por: Guan, Xiuwen, et al.
Publicado: (2019)

Plasma cell-free DNA and survival in non-small-cell lung cancer: A meta-analysis
por: Yi, Zongbi, et al.
Publicado: (2017)

Genome-wide chromosomal instability by cell-free DNA sequencing predicts survival in patients with metastatic breast cancer
por: Mo, Hongnan, et al.
Publicado: (2020)

Epithelial-Mesenchymal-Transition-Like Circulating Tumor Cell-Associated White Blood Cell Clusters as a Prognostic Biomarker in HR-Positive/HER2-Negative Metastatic Breast Cancer
por: Guan, Xiuwen, et al.
Publicado: (2021)

Landscape of somatic mutations in different subtypes of advanced breast cancer with circulating tumor DNA analysis
por: Yi, Zongbi, et al.
Publicado: (2017)

The association between early-onset cardiac events caused by neoadjuvant or adjuvant chemotherapy in triple-negative breast cancer patients and some novel autophagy-related polymorphisms in their genomic DNA: a real-world study
por: Liu, Binliang, et al.
Publicado: (2018)

Antibody-Drug Conjugates for the Treatment of HER2-Positive Breast Cancer
por: Najjar, Mariana K., et al.
Publicado: (2022)

Advances in Antibody-Drug Conjugates in the Treatment of HER2-Positive Breast Cancer
por: Yu, Yongchao, et al.
Publicado: (2022)

The molecular tumor burden index as a response evaluation criterion in breast cancer
por: Yi, Zongbi, et al.
Publicado: (2021)

ctDNA dynamics: a novel indicator to track resistance in metastatic breast cancer treated with anti-HER2 therapy
por: Ma, Fei, et al.
Publicado: (2016)

Prognostic Factors and a Model for Occult Breast Cancer: A Population-Based Cohort Study
por: Zhang, Di, et al.
Publicado: (2022)

Multi-omics fusion analysis models with machine learning predict survival of HER2-negative metastatic breast cancer: a multicenter prospective observational study
por: Wang, Jiani, et al.
Publicado: (2023)

Development and Validation of a New Clinical Prediction Model of Catheter-Related Thrombosis Based on Vascular Ultrasound Diagnosis in Cancer Patients
por: Liu, Binliang, et al.
Publicado: (2020)

Biomarkers of Everolimus Sensitivity in Hormone Receptor-Positive Breast Cancer
por: Yi, Zongbi, et al.
Publicado: (2017)

Antibody–Drug Conjugates (ADC) in HER2/neu-Positive Gynecologic Tumors
por: McNamara, Blair, et al.
Publicado: (2023)

Preparation and characterization of antibody-drug conjugates acting on HER2-positive cancer cells
por: Chiang, Zu-Chian, et al.
Publicado: (2020)

Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directions
por: Ferraro, Emanuela, et al.
Publicado: (2021)

The change of paradigm in the treatment of HER2-positive breast cancer with the development of new generation antibody-drug conjugates
por: Escrivá-de-Romaní, Santiago, et al.
Publicado: (2023)

HER2 heterogeneity and resistance to anti-HER2 antibody-drug conjugates
por: Ocaña, Alberto, et al.
Publicado: (2020)

Next-generation antibody–drug conjugates revolutionize the precise classification and treatment of HER2-expressing breast cancer
por: Dai, Lei-Jie, et al.
Publicado: (2023)

HER2 Directed Antibody-Drug-Conjugates beyond T-DM1 in Breast Cancer
por: Rinnerthaler, Gabriel, et al.
Publicado: (2019)

Antibody drug conjugates targeting HER2: Clinical development in metastatic breast cancer
por: Rassy, Elie, et al.
Publicado: (2022)

Population pharmacokinetics of trastuzumab emtansine (T-DM1), a HER2-targeted antibody–drug conjugate, in patients with HER2-positive metastatic breast cancer: clinical implications of the effect of covariates
por: Lu, Dan, et al.
Publicado: (2014)

Data reproducibility issues on evidence synthesis of adverse events associated with HER2-targeted antibody–drug conjugates
por: Wu, Dan-Na, et al.
Publicado: (2023)

Prognostic Value of the Serum HER2 Extracellular Domain Level in Breast Cancer: A Systematic Review and Meta-Analysis
por: Wu, Yun, et al.
Publicado: (2022)

Antibody-drug conjugates with HER2-targeting antibodies from synthetic antibody libraries are highly potent against HER2-positive human gastric tumor in xenograft models
por: Kuo, Wei-Ying, et al.
Publicado: (2018)

Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody–drug conjugate in development for the treatment of HER2-positive cancer
por: Girish, Sandhya, et al.
Publicado: (2012)

Multicomponent Conjugates of Anticancer Drugs and Monoclonal Antibody with PAMAM Dendrimers to Increase Efficacy of HER-2 Positive Breast Cancer Therapy
por: Marcinkowska, Monika, et al.
Publicado: (2019)

The Efficacy and Safety of Programmed Cell Death 1 and Programmed Cell Death 1 Ligand Inhibitors for Advanced Melanoma: A Meta-Analysis of Clinical Trials Following the PRISMA Guidelines
por: Guan, Xiuwen, et al.
Publicado: (2016)

HER2-targeted antibody–drug conjugates for breast cancer: ancestry and dose adjustment for thrombocytopenia
por: Rainone, Michael, et al.
Publicado: (2023)

Dynamics of Endocytosis and Degradation of Antibody-Drug Conjugate T-DM1 in HER2 Positive Cancer Cells
por: Liang, Keying, et al.
Publicado: (2021)

Novel Anti-HER2 Antibody-Drug Conjugates Versus T-DM1 for HER2-Positive Metastatic Breast Cancer After Tyrosine Kinase Inhibitors Treatment
por: Ji, Chenchen, et al.
Publicado: (2023)

HER3 targeting with an antibody‐drug conjugate bypasses resistance to anti‐HER2 therapies
por: Gandullo‐Sánchez, Lucía, et al.
Publicado: (2020)

Pyrotinib plus capecitabine could significantly improve overall survival in HER2-positive metastatic breast cancer
por: Guan, Xiuwen, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_klr6qdpaall13ef6k893b8i2oo